百時美施貴寶稱淋巴瘤藥物2期試驗數據積極

環球市場播報

2025/02/10

　　百時美施貴寶（Bristol Myers Squibb）公司周一宣佈，評估Breyanzi藥物用於治療復發難治性惰性B細胞非霍奇金淋巴瘤成人患者的 TRANSCEND FL二期試驗在邊緣區淋巴瘤隊列研究中達到了主要終點。

　　該2期試驗顯示了具有統計學和臨牀意義的總體緩解率（ORR）。它還達到了完全緩解率（CRR）的關鍵次要終點，未觀察到新的安全性信號。

　　百時美施貴寶公司指出：「憑藉這些數據，Breyanzi證明了其針對第五種癌症類型的療效和可控的安全性，這是所有針對CD19的CAR-T細胞療法中數據最高的。」

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：張俊 SF065

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2510386642"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510386642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510386642?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-02-10 23:11","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2510386642","market":"fut","top_or_hot":-1,"title":"百時美施貴寶稱淋巴瘤藥物2期試驗數據積極","media":"環球市場播報","content":"<html><body><div>\n<p>　　百時美<span><a href=\"https://laohu8.com/S/BMY\">施貴寶</a></span><span></span>（Bristol Myers Squibb）公司周一宣佈，評估Breyanzi藥物用於治療復發難治性惰性B細胞非霍奇金淋巴瘤成人患者的 TRANSCEND FL二期試驗在邊緣區淋巴瘤隊列研究中達到了主要終點。</p>\n<p>　　該2期試驗顯示了具有統計學和臨牀意義的總體緩解率（ORR）。它還達到了完全緩解率（CRR）的關鍵次要終點，未觀察到新的安全性信號。</p>\n<p>　　百時美施貴寶公司指出：「憑藉這些數據，Breyanzi證明了其針對第五種癌症類型的療效和可控的安全性，這是所有針對CD19的CAR-T細胞療法中數據最高的。」</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張俊 SF065</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百時美施貴寶稱淋巴瘤藥物2期試驗數據積極</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百時美施貴寶稱淋巴瘤藥物2期試驗數據積極\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">環球市場播報</strong><span class=\"h-time small\">2025-02-10 23:11</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p>　　百時美<span><a href=\"https://laohu8.com/S/BMY\">施貴寶</a></span><span></span>（Bristol Myers Squibb）公司周一宣佈，評估Breyanzi藥物用於治療復發難治性惰性B細胞非霍奇金淋巴瘤成人患者的 TRANSCEND FL二期試驗在邊緣區淋巴瘤隊列研究中達到了主要終點。</p>\n<p>　　該2期試驗顯示了具有統計學和臨牀意義的總體緩解率（ORR）。它還達到了完全緩解率（CRR）的關鍵次要終點，未觀察到新的安全性信號。</p>\n<p>　　百時美施貴寶公司指出：「憑藉這些數據，Breyanzi證明了其針對第五種癌症類型的療效和可控的安全性，這是所有針對CD19的CAR-T細胞療法中數據最高的。」</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張俊 SF065</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-02-10/doc-ineizkuz3946254.shtml\">環球市場播報</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-02-10/doc-ineizkuz3946254.shtml","article_id":"2510386642","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510386642","pubTimestamp":1739200260,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"百時美施貴寶（Bristol Myers Squibb）公司周一宣佈，評估Breyanzi藥物用於治療復發難治性惰性B細胞非霍奇金淋巴瘤成人患者的 TRANSCEND FL二期試驗在邊緣區淋巴瘤隊列研究中達到了主要終點。\n　　該2期試驗顯示了具有統計學和臨牀意義的總體緩解率（ORR）。它還達到了完全緩解率（CRR）的關鍵次要終點，未觀察到新的安全性信號。\n　　百時美施貴寶公司指出：「憑藉這些數據，Breyanzi證明了其針對第五種癌症類型的療效和可控的安全性，這是所有針對CD19的CAR-T細胞療法中數據最高的。」\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張俊 SF065","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BMY":"施贵宝","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4007":"制药","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0237698245.USD":"富达环球地产基金A","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC"},"translate_title":"Bristol-Myers Squibb says lymphoma drug phase 2 trial data is positive","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"百時美施貴寶（Bristol Myers Squibb）公司周一宣佈，評估Breyanzi藥物用於治療復發難治性惰性B細胞非霍奇金淋巴瘤成人患者的 TRANSCEND FL二期試驗在邊緣區淋巴瘤隊列研究中達到了主要終點。\n　　該2期試驗顯示了具有統計學和臨牀意義的總體緩解率（ORR）。它還達到了完全緩解率（CRR）的關鍵次要終點，未觀察到新的安全性信號。\n　　百時美施貴寶公司指出：「憑藉這些數據，Breyanzi證明了其針對第五種癌症類型的療效和可控的安全性，這是所有針對CD19的CAR-T細胞療法中數據最高的。」\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}